Emgality demonstrated significant response rates in the reduction of mean monthly MHDs in any given month vs placebo1
ap<0.001 vs placebo.
Up to 62% of patients had a ≥50% reduction of monthly MHDs in any given month, on average (p<0.001)1
Up to 39% of patients achieved a ≥75% reduction of monthly MHDs in any given month, on average (p<0.001)1
Up to 1 in 7 patients (16%) were 100% migraine headache-free in any given month, on average (p<0.001)1
100% reduction of monthly MHDs in at least 1, 2, or 3 months12
Post-hoc analyses of EVOLVE-1 and EVOLVE-2 pooled data. Results reported are simple calculations of percentages. As these analyses are post hoc, no conclusions of statistical or clinical significance can be drawn.
≥50% reduction of monthly MHDs in preventive naïve and prior preventive failures13-15
Post-hoc analysis of EVOLVE-1 and EVOLVE-2 pooled data. The studies were not adequately powered nor error-controlled for subgroup analyses. Treatment differences observed in these subgroups cannot be regarded as statistically significant. Patients were excluded from the studies if they had previously failed to have an efficacy response to ≥3 classes of migraine preventive treatments with Level A or B efficacy according to the American Academy of Neurology’s Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults as well as botulinum toxin A or B. Assignment to the subgroup of patients who were naïve, failed >1, and failed ≥2 preventives was based on patient report of previous discontinuation of a migraine preventive due to lack of efficacy, suboptimal efficacy, or intolerability.16
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.